Dean F. Bajorin
- Surgery top 0.02%
- Bladder and Urothelial Cancer Treatments 293
- Urinary and Genital Oncology Studies 136
- Testicular diseases and treatments 118
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers 102
- Urology top 0.1%
- Reproductive Medicine top 0.5%
- Ovarian cancer diagnosis and treatment 30
- Pulmonary and Respiratory Medicine top 0.2%
- Renal cell carcinoma treatment 45
-
- Neuroblastoma Research and Treatments 58
-
- Multiple and Secondary Primary Cancers 51
Dean F. Bajorin
473 papers receiving 21.0k citations
Hit Papers
Peers
Comparison fields: 5 of 148
- Surgery 15.6k
- Oncology 8.0k
- Urology 1.6k
- Reproductive Medicine 1.5k
- Pulmonary and Respiratory Medicine 4.9k
Countries citing papers authored by Dean F. Bajorin
This map shows the geographic impact of Dean F. Bajorin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dean F. Bajorin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dean F. Bajorin more than expected).
Fields of papers citing papers by Dean F. Bajorin
This network shows the impact of papers produced by Dean F. Bajorin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dean F. Bajorin. The network helps show where Dean F. Bajorin may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Dean F. Bajorin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 4 | |
| 7 | 2023 | 14 | |
| 8 | 2021 | 30 | |
| 9 | 2021 | 21 | |
| 10 | 2020 | 20 | |
| 11 | 2017 | 189 | |
| 12 | Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinomabreakdown → | 2017 | 2374 |
| 13 | Genome Sequencing Identifies a Basis for Everolimus Sensitivitybreakdown → | 2012 | 480 |
| 14 | 2010 | 147 | |
| 15 | 2006 | 96 | |
| 16 | 2006 | 75 | |
| 17 | 2000 | 2 | |
| 18 | 2000 | 85 | |
| 19 | 1998 | 6 | |
| 20 | Identification and management of poor risk patients with germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. | 1988 | 20 |
About Dean F. Bajorin
Dean F. Bajorin is a scholar working on Surgery, Oncology, Neurology, Pulmonary and Respiratory Medicine and Reproductive Medicine, having authored 492 papers that have together received 21.4k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (293 papers), Urinary and Genital Oncology Studies (136 papers), Testicular diseases and treatments (118 papers), Cancer Immunotherapy and Biomarkers (102 papers), Neuroblastoma Research and Treatments (58 papers), Multiple and Secondary Primary Cancers (51 papers), Renal cell carcinoma treatment (45 papers) and Ovarian cancer diagnosis and treatment (30 papers). The work is most often cited by research in Surgery (15.6k citations), Oncology (8.0k citations), Urology (1.6k citations), Reproductive Medicine (1.5k citations) and Pulmonary and Respiratory Medicine (4.9k citations). Dean F. Bajorin has collaborated with scholars based in United States, Spain and Canada. Frequent co-authors include George J. Bosl, Robert J. Motzer, Harry W. Herr, Howard I. Scher, Joaquim Bellmunt, Joel Sheinfeld, Ronald de Wit, Madhu Mazumdar, Nicholas J. Vogelzang and S. Machele Donat. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Urology, Cancer, Annals of Oncology and Clinical Genitourinary Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.